US and Canadian cannabis stocks were largely on the rise Tuesday after Aurora issued its quarterly earnings report during after hours trading Monday.
Brett D. Marchand was appointed Aphria’s Senior Vice President of Supply Chain Monday. According to the CBC, shareholders have implicated Aphria in two class-action lawsuits due to inadequate disclosures regarding the acquisition of its Colombian, Argentinian, and Jamaican assets. Allegations of fraud and insider dealing were first launched against Aphria in December 2018 by Quintessential and Hindenburg Research.
Monday Green Growth Brands announced that it has entered into an agreement with the Simon Property Group. The agreement will give Green Growth a national footprint with 108 US mall locations, where the company plans to distribute its CBD product lines. Green Growth recently announced the execution of a licensing agreement with Authentic Brands Group and the Greg Norman Brand for the manufacturing of CBD personal care products. The deal includes a CBD supply agreement with Tilray.
Cronos is under the microscope in anticipation of its Q4 2018 earnings report. The company’s report is expected April 29, 2019. Cronos is driven by a $1.8B investment from tobacco giant Altria Group. Though the company has been surging on the sentiment of institutional investment, the company only reported $3.8M in revenue in Q3 2018. In the coming moneth investors will be looking for signs that Cronos has increased its production and manufacturing capacity. After skyrocketing more than 110% year to date, GMP Securities’ Martin Landry downgraded the company from a “hold” rating to a “buy” rating and reiterated a price target of $18.
Canopy Growth is scheduled to release its quarterly earnings report on Thursday with expected revenues to exceed $63M according to The Street. According to Yahoo Finance, Canopy’s report should reflect gains from an expanding patient base and the launch of its new soft gel capsules with continuous and discrete dosing. Recently the company announced it is investing an additional $500M in the US market by adding hemp production in Rhode Island and two other states.
Organigram issued its Q1 2019 earnings report Monday. The company announced $12.4M in net sales, a 287% upside from the previous quarter. Organigram shares have soared over 45% in 2019. Last week Organigram announced the expansion of its production facility. The expansion will more than triple the company’s annual production capacity to 113K kilograms once completed.
Valens GroWorks received a bullish write up from The Street recently, noting AltaCorp’s “outperform” rating on the stock. AltaCorp told Midas Letter that it views Valens as “one of the premier businesses in the entire sector.” According to AltaCorp, Valens also has a noteworthy partnership with Thermo Fisher Scientific. Last week Haywood Capital Markets initiated coverage on Valens, giving the company a “buy” rating and a target price of CA$5.25. The company has secured extraction supply agreements with both Canopy Growth and Organigram Holdings. Currently the company is expanding its production capacity to 150K kilograms annually.
Zynerba has gained 20.47% according to Zacks who issued a “buy” rating on the company. Analysts have given the stock an average 12-month price target of $16.40, representing a 219.0% upside. Zynerba is on track to report results from its clinical study of CBD used in the treatment children and adolescents with Fragile X Syndrome, CEO Armando Anido told Proactive Investors at the 2019 BIO CEO and Investor Conference. The company also completed enrollment in its Phase 2 clinical trial for epileptic encephalopathy and expects to report results in the third quarter of 2019. Zynerba has an average “hold” rating from analysts, and a consensus price target of $15.88.
Tilray is scheduled to issue its Q4 2018 earnings report after the bell today. According to Yahoo Finance in Tilray’s last quarterly report the company exceeded earnings expectations by nearly 43%. Last week Tilray teamed up with Green Growth Brands and Authentic Brands to bring cannabis infused products to US markets. Recently Tilray announced the expansion of its global senior leadership team with the appointment of Sascha Mielcarek as Managing Director of European Operations. Zacks currently has a “hold” rating on the stock.
Last Friday The Green Organic Dutchman announced that it has secured a supply agreement with the Ontario Cannabis Retail Corporation.
Innovative Industrial Properties recently announced the acquisition of its first California property in Sacramento. The 43,000 square-foot facility spreads IIPRs footprint across ten states. Last week the company also announced the acquisition of a 75K square-foot facility on a ten-acre property in Barry Illinois.
Aurora Cannabis issued its Q2 2019 earnings report late Monday, with quarterly revenue skyrocketing to CA$54.2M. Aurora’s surging revenue hardly kept up with their gigantic losses however. The canadian producer posted a quarterly loss of CA$237.8M. Monday the company announced it has exported its first shipment of cannabis oil to the UK.
All eyes are on Neptune Wellness in anticipation of its third quarter results which will be posted tomorrow. Roth Capital rated NEPT as a “buy” with a $5 price target last week. The company was also recently given a “strong buy” rating from Zacks, with a 12-month consensus price target of $6.06. Bidask Club downgraded Neptune from a “hold” rating to a “sell” rating Saturday morning.
Acreage Holdings’ John Boehner has formed a new cannabis lobbying effort called the National Cannabis Roundtable. The aim of the Roundtable is to reform marijuana taxation and legalization. Recently Acreage announced it intends to amass 78 medical and recreational dispensaries in 19 states over the next year.
GW Pharmaceuticals is scheduled to release its earnings report for the period that ended Dec. 31, 2018 on February 26, 2019. Monday the stock saw its Relative Strength Rating rise from 63 to 85. According to Investors Business Daily GWPH is building a cup without a handle with a buy point at $179.75. Last week Zacks reiterated its “hold” rating for the company.
According to La Presse Hexo Corps’ Vincent Chiara is pursuing legal action against Stockhouse users for defamation. Users on the platform made several comments, some regarding Chiara allegedly having ties to a mafia crime family. The comments were removed by Stockhouse per Chiara’s request. Chiara is now asking the courts to compel the ISPs to reveal the user identities so Chiara can pursue legal action. Hexo gained a massive 65% in the month of January.
The New York Medical Cannabis Industry Association is distancing itself from MedMen Enterprises after insiders of the company were accused of making of sexist and racist remarks. The association is also highly concerned about financial corruption among MedMen’s top executives. Former company CFO James Parker filed a lawsuit against the company recently, alleging top executives in the company forced him to “choose between complying with his fiduciary duty to the company and its shareholders or turning a blind eye and a deaf ear to improper and unlawful behavior”. This is the second lawsuit to accuse MedMen of fiduciary abuses launched in the last month.
KushCo announced Monday that the company is restructuring its executive leadership team. Effective March 1, 2019 Jim McCormick will be stepping down from his position as the company’s COO and will be replaced by Rodrigo de Oliveira. Oliveira is being promoted from Vice President of Operations and will serve as interim COO. The company’s president Jason Vegotsky is being promoted to Chief Revenue Officer, and Carmen Lam, who is the company’s Regional Sales Director is being promoted to Senior Vice President.
Trulieve announced Monday that it has signed an agreement with Love’s Oven LLC to bring their cannabis infused confections and other products to Florida’s patient base of 180K people. The decision is somewhat premature considering edibles are still illegal in Florida. Last week Beacon Securities’ Russell Stanley reported Trulieve has 24 dispensaries in Florida and 60% of the state’s sales volume. Stanley projects a 2019 EBITDA of $90.7M for Trulieve, with revenue of $208.7M. The analyst set a price target of CA$28.00 for the company and reiterated his “buy” rating.
MariMed announced Monday that it has converted its initial $30M purchase of debentures into GenCanna Global common stock.
Auxly announced it has terminated its JV with FSD Pharma due to contractual breaches and significant concerns over the building’s infrastructure. FSD failed to remedy the concerns and terminated its contract with Auxly. FSD issued a press release denying the allegations. Auxly was given an “outperform” rating from AltaCorp Capital recently.
It is worth noting that FSD has also fired its recently hired CEO from GW Pharmaceuticals. The company has issued a flurry of press releases recently, most of which have little substance. This company is on our radar as a potential risk to investors.
iAnthus has increased its footprint to eleven states after receiving its most recent license from New Jersey. Last week, in a $1.6B merger, iAnthus and MPX Bioceutical Corporation (CSE: MPX) (OTC: MPXEF) announced the closing of the agreement whereby iAnthus will acquire all of MPX’s issued and outstanding shares. Beacon Securities analyst Russel Stanley reiterated his “buy” rating and gave the company a price target of a whopping $16.00, implying a 129% return.
Namaste has been shrouded in drama recently. The company announced that it has terminated CEO Sean Dollinger due to evidence of self-dealing. Canada News Wire issued a correction stating that Namaste has not brought legal action against Dollinger. According to the Globe and Mail Dollinger is disputing the company’s dismissal and is seeking an injunction to retain his role as CEO. The company issued a press release last Tuesday that Dollinger is counter-suing the company.
New Age Beverages is expected to release its quarterly earnings report tomorrow. Over 6 million previously locked up shares of NBEV poured into the market last week. According to White Diamond Research, NBEV has burned through most of its cash raise from a non-core acquisition and expects the company to initiate more rounds of equity financing in the near future. BidaskClub downgraded NBEV from a “buy” to a “hold” rating on Saturday. The company gained a whopping 36.7% in January according to S&P Global Market Intelligence. According to Zacks the company is expected to announce $14.06M in sales for the current fiscal quarter. Average analyst expectations project New Age Beverage to post full-year sales of $52.23M for the current financial year.
Supreme cannabis issued its Q2 2019 financial results today, reflecting a 359% increase from Q2 2018. The company reported quarterly revenue of $7.72M with a net loss of $1.55M. Last Monday Supreme Cannabis began listing on the Toronto Stock Exchange. Supreme plans to release its second quarter earnings report on Tuesday for the three-month period that ended on December 31, 2018. The company’s subsidiary 7Acres announced last Thursday that it has entered into a supply agreement with the New Brunswick Liquor Corporation to supply cannabis to its retail stores. The agreement will expand Supreme’s footprint into New Brunswick and Saskatchewan, upping the company’s provincial count from 6 to 8.
Amyris and the Infectious Disease Research Institute announced the receipt of a $4.4M grant from the National Institute of Allergy and Infectious Diseases. Amyris was selected as a partner because of its record of success in engineering molecules that are pure, sustainable, and achieved at a low cost. Monday Amyris announced the appointment of Oreste Fieschi as President of Sweeteners & Ingredients. According to Zacks, analysts expect the company to post $100.76M in sales for the current fiscal quarter. Amyris announced a $255M binding term sheet for a planned cannabinoid facility, licensing, and commercialization partnership last week. The confidential partner will receive payments linked to milestones that are expected over the next 12-36 months.
New Level Brands is scheduled to release its quarterly earnings report this Friday. Chairman Emeritus and Chief Brand Strategist at Level Brands was recently appointed to the board of the NFL Players Inc — the licensing and marketing arm of the NFL Players Association. In December the company acquired North Carolina-based cbdMD. cbdMD was recently featured in Elle Magazine as the first national CBD oil advertiser.
The North American Marijuana Index tracks the leading cannabis stocks in the US and Canadian Sectors. The Index gained 1.63% and was trading at $275.11.